-transparent.png){kind=logo}
Four patients with acute lymphocytic leukemia previously treated with conventional chemotherapy received intramuscular L-asparaginase in combination with other chemotherapy for reinduction and maintenance therapy. These patients received the L-asparaginase for 8, 14, 27, and 34+ months without demonstrating any significant adverse effects. Only 1 of the 4 was clearly resistant to the other chemo-therapy, and 3 of 4 had recurrence of their disease while receiving L-asparaginase. L-asparaginase can be added to reinduction and maintenance regimens of patients resistant to other chemotherapy and is well tolerated for long periods when given intramuscularly weekly with other immunosuppressant agents.
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1978,
Medical and pediatric oncology,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 2015,
Future oncology (London, England),
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
November 1981,
European journal of pediatrics,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
August 1989,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1990,
Haematologica,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1979,
The American journal of pediatric hematology/oncology,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1977,
Medical and pediatric oncology,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
June 2009,
Zhongguo shi yan xue ye xue za zhi,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1973,
Bibliotheca haematologica,
L Sieger, and
G Higgins, and
J Ortega, and
N Shore, and
K Williams
January 1970,
Gan no rinsho. Japan journal of cancer clinics,
